Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David E. Lanfear
The environmental exposome in heart failure risk and progression
5 hours ago America’s heart health is improving in one key way, but a newly defined syndrome is raising alarms. The findings come from the American Heart Association (AHA), which reported improvements in life expectancy and fewer heart attacks and strokes compared to 2023. New to this year’s report is a focus on …
ACT Brief: AI Decision-Making, Sponsor Oversight Trends, and HHS Label Changes
News|Podcasts|November 12, 2025 In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss evolving sponsor oversight in site selection and protocol design, and review the FDA’s decision to update menopausal hormone therapy labels for clarity and safety. This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations.
The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants
What is the current knowledge on the topic? ○ Beta-blockers are a cornerstone treatment to prolong the survival of patients with heart failure with reduced ejection fraction (HFrEF), but some HFrEF patients' responses to beta-blockers are variable and unpredictable. Previous pharmacogenetic findings for the effects of genetic variants in beta-blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. What question did this study address?
HFA 23: Diagnosis in Heart Failure in Women
Video HFA 23: Diagnosis in Heart Failure in Women Published: Views: 17 Likes: 0 ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database. Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men. Interview Questions: 1.
Gut Microbiome in Cardiovascular Disease and Heart Failure: Seeing the Iceberg Below Its Surface
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device:
Introduction Over past decades, left ventricular assist devices (LVADs) have emerged as critical life-prolonging therapy for patients with advanced heart failure refractory to medical therapy.1 As clinical experience and pump technology improved, the current-era survival with LVADs has improved to allow for widespread use, even among those ineligible for heart transplantation.2,3 Advances in overcoming hemocompatibility-related adverse events (de novo pump thrombosis, ischemic and hemorrhagic...
Racial Inequities in Access to Ventricular Assist Device and Transplant Persist After Consideration for Preferences for Care: A Report From the REVIVAL Study
Originally publishedhttps://doi.org/10.1161/CIRCHEARTFAILURE.122.009745Circulation: Heart Failure. 2022;0:e009745 Abstract Background: Racial disparities in access to advanced therapies for heart failure (HF) patients are well documented, although the reasons remain uncertain. We sought to determine the association of race on utilization of ventricular assist device (VAD) and transplant among patients with access to care at VAD centers and if patient preferences impact the effect.
Video: Electronic health records could be ‘rapidly adopted’ in HF treatment
April 19, 2022 1 min watch Source/Disclosures Source: Healio Interview Disclosures: Lanfear reports receiving research grants from and consulting or serving on an advisory board for Amgen, receiving research grants from Somalogic and consulting or serving on an advisory board for Abbott, Cytokinetics, DCRI, Janssen, Martin and Ortho Diagnostics.
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial - Nature Medicine
Abstract Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion.
Redwood-HCM: Second-Generation Drug for HCM Well-Tolerated by Patients
- I'm Marty Maron. I'm the Director for the Hypertrophic Cardiomyopathy Centre and Research Institute at Tufts Medical Centre. I'm also Co-Director of the Chanin T. Mast Hypertrophic Cardiomyopathy Centre in Morristown, New Jersey and Morristown Medical Centre. And the study that we're going to be talking about today is Redwood-HCM. Unmet need in the treatment of hypertrophic cardiomyopathy (HCM) So the focus of this trial and study, Redwood-HCM, is on the obstructive form of HCM.
Remote Monitoring May Reduce HFrEF Adverse Events
- Hi, my name is Larry Allen. I'm a transplant cardiologist at the University of Colorado in Denver. What is the importance of MANAGE-HF? Patients with heart failure and reduced ejection fraction typically suffer from chronic symptoms. And it's a relapsing and remitting disease where patients are sometimes better and then have acute exacerbations of their illness. There's been much interest in trying to predict or anticipate those decompensations in patients.
Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure:
Abstract Objectives This study sought to determine cardiopulmonary exercise (CPX) predictors of the combined outcome of durable mechanical circulatory support (MCS), transplantation, or death at 1 year among patients with ambulatory advanced heart failure (HF). Background Optimal CPX predictors of outcomes in contemporary ambulatory advanced HF patients are unclear.
Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects
To view the full text, please login as a subscribed user or purchase a subscription . Click here to view the full text on ScienceDirect. Inhaled corticosteroids (ICSs) are the preferred treatment for achieving asthma control. However, little is known regarding the factors contributing to treatment response and whether treatment response differs by population group.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David E.
Contact David E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack